President and CEO, Tango Therapeutics
Venture Partner, Third Rock Ventures
Dr. Barbara Weber is a scientific advisor to FogPharma and joined Third Rock Ventures in 2015 to focus on oncology research and development opportunities throughout the portfolio. In that role, she served as the interim CMO for Neon Therapeutics from launch in 2015 until September 2017. She also played a leadership role in creating Relay Therapeutics, launched in March 2016. However, her passion was always for a cancer therapeutics company to take full advantage of recent advances in cancer genetics to take the next big step forward for patients. That company is Tango Therapeutics. Tango started as an idea at Third Rock in 2015 and moved to public launch with a $55M Series A from Third Rock Ventures in March 2017, with Dr. Weber as the interim CEO and 6 full-time employees. In September 2017, Dr. Weber accepted the position as the permanent, full time CEO of Tango, and leads a team of 20 experienced cancer geneticists and drug developers.
Prior to joining Third Rock, Dr. Weber held the position of senior vice president and global head of oncology translational medicine at Novartis from 2009 to 2015. Prior to joining Novartis, Dr. Weber served as vice president oncology discovery and translational medicine at GlaxoSmithKline from 2005 to 2009. Until 2005, Dr. Weber was a professor of medicine and genetics at the University of Pennsylvania School of Medicine, leading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program.
Dr. Weber is a member the honorary societies American Association of Physicians and the American Society for Clinical Investigation, of which she served as president in 2005. Dr. Weber also has served on numerous scientific advisory boards and on the board of directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. Dr. Weber is a graduate of the University of Washington School of Medicine. She completed her residency in Internal Medicine at Yale University School of Medicine and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute.